Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort
Granulomatosis with Polyangiitis
The incidence of solid malignancy remained increased during long-term followup of the WGET cohort. However, this could not be attributed solely to etanercept exposure during the trial. Anti-TNF therapy with etanercept appears to further increase the risk of malignancy observed in patients with GPA treated with cytotoxic agents and should be avoided in these patients.